AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Cytek Biosciences, Inc.
Video analysis: CTKB
All videosNo video analysis for this stock yet. Request one from our team.
News: CTKB
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
FREMONT, Calif., and HAMBURG, Germany, Sept.
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.
Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB
Deutsche Bank AG bought a new position in Cytek Biosciences, Inc. (NASDAQ: CTKB) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 111,932 shares of the company's stock, valued at approximately $496,000. Deutsche Bank AG owned approximately 0.09% of Cytek Biosciences as of
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.01 per share a year ago.
